The Pharmaceutical Benefits Advisory Committee has approved pre-filled syringes for subcutaneous administration of methotrexate (Trexject) for the treatment of rheumatoid arthritis when oral methotrexate is unsuitable. The approval at their March meeting overturns a 2016 decision rejecting the application due to concerns about cost minimisation with the 50mg vial of methotrexate. However the latest decision ...
Trexject gets the tick from PBAC second time around
17 May 2017